Cargando…

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulaiman, Raed, De, Pradip, Aske, Jennifer C., Lin, Xiaoqian, Dale, Adam, Koirala, Nischal, Gaster, Kris, Espaillat, Luis Rojas, Starks, David, Dey, Nandini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342322/
https://www.ncbi.nlm.nih.gov/pubmed/37446260
http://dx.doi.org/10.3390/ijms241311079
_version_ 1785072471353851904
author Sulaiman, Raed
De, Pradip
Aske, Jennifer C.
Lin, Xiaoqian
Dale, Adam
Koirala, Nischal
Gaster, Kris
Espaillat, Luis Rojas
Starks, David
Dey, Nandini
author_facet Sulaiman, Raed
De, Pradip
Aske, Jennifer C.
Lin, Xiaoqian
Dale, Adam
Koirala, Nischal
Gaster, Kris
Espaillat, Luis Rojas
Starks, David
Dey, Nandini
author_sort Sulaiman, Raed
collection PubMed
description The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass.
format Online
Article
Text
id pubmed-10342322
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103423222023-07-14 Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers Sulaiman, Raed De, Pradip Aske, Jennifer C. Lin, Xiaoqian Dale, Adam Koirala, Nischal Gaster, Kris Espaillat, Luis Rojas Starks, David Dey, Nandini Int J Mol Sci Article The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass. MDPI 2023-07-04 /pmc/articles/PMC10342322/ /pubmed/37446260 http://dx.doi.org/10.3390/ijms241311079 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sulaiman, Raed
De, Pradip
Aske, Jennifer C.
Lin, Xiaoqian
Dale, Adam
Koirala, Nischal
Gaster, Kris
Espaillat, Luis Rojas
Starks, David
Dey, Nandini
Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title_full Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title_fullStr Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title_full_unstemmed Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title_short Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
title_sort tumor-tme bipartite landscape of pd-1/pd-l1 in endometrial cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342322/
https://www.ncbi.nlm.nih.gov/pubmed/37446260
http://dx.doi.org/10.3390/ijms241311079
work_keys_str_mv AT sulaimanraed tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT depradip tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT askejenniferc tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT linxiaoqian tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT daleadam tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT koiralanischal tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT gasterkris tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT espaillatluisrojas tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT starksdavid tumortmebipartitelandscapeofpd1pdl1inendometrialcancers
AT deynandini tumortmebipartitelandscapeofpd1pdl1inendometrialcancers